Clinical Study
Higher Levels of Autoantibodies Targeting Mutated Citrullinated Vimentin in Patients with Psoriatic Arthritis Than in Patients with Psoriasis Vulgaris
Table 2
Clinical and laboratory characteristics of patients in the psoriatic arthritis (PsA) and psoriasis vulgaris (PsO) groups.
| | Variable | PsA group
() | PsO group
() |
| | Anti-MCV positivity (%) | 24 | 8 | | Level of anti-MCV (mean ± SD; U/mL) | 30.32 ± 82.14 | 8.71 ± 7.41 | | ANA positivity (%)† | 38 | Not measured | | RF positivity (>9 U/mL; %)† | 11 | Not measured | | Active psoriatic lesions in the skin | 100 | 95 | | PASI score (mean ± SD) | — | 5.84 ± 6.75 | | Nail psoriasis (%) | 28 | 43 | | Scalp psoriasis (%) | 72 | 57 | | Plaques on the face (%) | 11 | 14 | | Plaques on the upper limbs (%) | 61 | 71 | | Plaques on the trunk (%) | 30 | 48 | | Plaques on the perineum (%) | 15 | 7 | | Plaques on the lower limbs (%) | 59 | 88 | | Arthritic features | | | | DAS28 score (mean ± SD) | 4.51 ± 1.00 | — | | DIP involvement (%) | 33 | — | | Erosion (%) | 24 | — | | Tender joint count (mean ± SD) | 9.78 ± 5.90 | — | | Back (%) | 48 | — | | Shoulders (%) | 37 | — | | Elbows (%) | 15 | — | | Wrists (%) | 46 | — | | Hands (%) | 67 | — | | Hips (%) | 17 | — | | Knees (%) | 35 | — | | Feet (%) | 61 | — | | Swollen joint count (mean ± SD) | 2.67 ± 3.19 | — | | Swollen shoulder (%) | 0 | — | | Swollen elbow (%) | 2 | — | | Swollen wrist (%) | 9 | — | | Hand joints (%) | 43 | — | | Swollen knee (%) | 11 | — | | Feet joints (%) | 26 | — |
|
|
Anti-MCVs: antibodies against mutated citrullinated vimentin, ANA: anti-nuclear antibody, RF: rheumatoid factor, DIP: distal interphallangeal, PASI: psoriasis area and severity index, DAS28: disease activity score.
|
